Japanese subpopulation analysis of the RENAAL, the landmark trial, is welcomed by our society

Clin Exp Nephrol. 2006 Sep;10(3):226-7. doi: 10.1007/s10157-006-0430-y.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Angiotensin II Type 1 Receptor Blockers / adverse effects
  • Angiotensin II Type 1 Receptor Blockers / pharmacology
  • Angiotensin II Type 1 Receptor Blockers / therapeutic use*
  • Clinical Trials as Topic
  • Diabetes Mellitus, Type 2 / complications*
  • Diabetes Mellitus, Type 2 / epidemiology
  • Diabetes Mellitus, Type 2 / ethnology
  • Diabetic Nephropathies / drug therapy*
  • Diabetic Nephropathies / epidemiology
  • Diabetic Nephropathies / ethnology
  • Diabetic Nephropathies / prevention & control
  • Humans
  • Japan / epidemiology
  • Japan / ethnology
  • Kidney Diseases / drug therapy*
  • Kidney Diseases / epidemiology
  • Kidney Diseases / ethnology
  • Kidney Diseases / prevention & control
  • Kidney Failure, Chronic / epidemiology
  • Kidney Failure, Chronic / physiopathology
  • Kidney Failure, Chronic / prevention & control
  • Losartan / adverse effects
  • Losartan / pharmacology
  • Losartan / therapeutic use*
  • Renin-Angiotensin System / drug effects
  • Renin-Angiotensin System / physiology

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Losartan